Ask HopeStage to review this study with me
Study ID: EUCTR 2021-001333-38. We help you review the study, but cannot decide medical eligibility.
RecruitingEUCTR 2021-001333-38
Cognitive effects of adjuntive Vortioxetine in early Schizophrenia
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
SchizophreniaDrug
Check recruitment and locations
EU CTR and CTIS records checked by HopeStage on . Registry information can change. Always confirm availability with the research team.
This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.
View the historical EU CTR record
Current CTIS country statuses
- Spain : Authorised, recruiting
Historical EU CTR country statuses
- Spain : Ongoing
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Spain · 1 site
- University Hospital Virgen Del Rocio S.L. — PsiquiatrySevillaSite status: Not listed — confirm with the team
Key information made simple
What the source confirms
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
What should you check before joining?
Check the official protocol for eligibility, treatment, visits and assessments. If recruitment is listed, confirm with the team that a specific centre is still accepting participants before taking any next step.
Your next step
Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Spain
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2021-001333-38
- Official title
- Cognitive effects of adjuntive Vortioxetine in early Schizophrenia
- Official source
- Official registry link
Want help reviewing this study?
Study ID: EUCTR 2021-001333-38. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What does the official source confirm?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Is this study recruiting?
The public registry lists this study as recruiting. Individual sites may have different statuses. The research team must confirm whether a site is open and whether you meet the criteria.
How can I check the participation requirements?
Check the official protocol for the criteria, treatment and planned assessments. The research team must confirm visits, risks, open centres and your eligibility.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingEUCTR 2021-000350-26
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
RecruitingNCT05511363
KarXT for Schizophrenia
The registry lists this study as recruiting. Study locations are listed in the United States, in France, in the United Kingdom, ... Confirm recruitment at each site. It is testing KarXT for Schizophrenia.
RecruitingNCT06540833
ITI-1284 for Schizophrenia
The registry lists this study as recruiting. Study locations are listed in the United States, in Bulgaria, in Croatia, ... Confirm recruitment at each site. It is testing ITI-1284 for Schizophrenia.